Urethral stricture treatment devices market seen reaching $2.14B by 2030

The market for urethral stricture treatment devices is projected to grow from $1.47 billion in 2025 to $1.59 billion in 2026, driven by rising urological disease, aging populations and more minimally invasive care. North America held the largest share in 2025, while The Business Research Company expects steady expansion through 2030.

Why it matters: - Urethral stricture treatment devices support patients with narrowed urethras that can cause urinary retention and difficult urination. - Demand for these devices is rising alongside more benign prostatic hyperplasia, neurogenic bladder disorders and catheter-related complications. - The market outlook suggests continued spending on urology tools, especially for minimally invasive and outpatient care.

What happened: - The Business Research Company released a market report on urethral stricture treatment devices on September 1, 2026. - The report says the market will rise from $1.47 billion in 2025 to $1.59 billion in 2026, a CAGR of 8.0%. - The same report projects the market will reach $2.14 billion by 2030, at a CAGR of 7.8%. - Download a free sample of the report. - View the full market report.

The details: - Urethral stricture treatment devices are used to widen or bypass a narrowed urethral segment and restore urine flow. - The devices are used in both surgical and non-surgical treatment settings. - The report identifies several growth drivers: rising urological disorders, an aging male population, more catheterization procedures, expansion of hospital urology departments and advances in surgical treatments for strictures. - Looking ahead, the report points to more minimally invasive urology practices, demand for long-term stent solutions, adoption of advanced biomaterials, growth in outpatient procedures and more personalized urology devices. - Expected product trends include minimally invasive stricture management techniques, balloon dilation technologies, improved urethral stent designs, enhanced catheter materials and more outpatient urological interventions. - The report notes BPH and neurogenic bladder disorders as major contributors to market growth. - BPH can raise the risk of urethral stricture because prostate enlargement may lead to urinary obstruction. - Treatment options listed in the report include dilators, stents and urethrotomy instruments. - A September 2023 report from the Royal Pharmaceutical Society said about 3 million people in the UK are affected by BPH. - The same report said BPH prevalence is about 50% among men ages 60 to 70 and nearly 90% among those over 80.

Between the lines: - The market case is being driven less by one device category and more by a broader shift toward less invasive and more durable urology interventions. - The emphasis on biomaterials, stent design and outpatient procedures suggests manufacturers are competing on patient recovery time, comfort and procedure efficiency. - North America's leading share in 2025 points to a mature market with established reimbursement, clinical adoption and specialty care infrastructure.

What's next: - The report expects the market to keep expanding through 2030 as minimally invasive urology and outpatient treatment gain ground. - Regional coverage in the report includes Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The Business Research Company said its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspot infographics and updated graphics and tables. - The company also provided contact details for expert outreach and promotion of the report.

The bottom line: - Urethral stricture treatment devices are moving with broader urology demand, and the market appears set for steady growth as care shifts toward less invasive procedures and outpatient settings.